These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2016-000945-29 Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) Attività di Abiraterone nel trattamento della sindrome di Cushing in pazie... bad-data
Completed, but no date, and reported results 2016-004210-10 A PILOT PHASE IV STUDY TO EVALUATE VARIATION IN BONE MINERAL DENSITY, LEAN AND FAT BODY MASS MEASURED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN PATIENTS WITH PROSTATE CANCER WITHOUT BONE METASTASIS TREA... bad-data
Ongoing 2017-000305-21 Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, mul... not-yet-due
Ongoing 2017-001591-35 Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Carcinoma progressing after previous chemotherapy l... not-yet-due
Ongoing 2018-000580-90 Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Multicenter randomized open-label phase III tri... not-yet-due
Ongoing 2019-000364-24 Randomized open label multicentric phase II trial of Adjuvant RadioChemotherapy, Concurrent versus Sequential, in resected non-small cell lung cancer (NSCLC) patients with mediastinal involvement (pN2... not-yet-due
Completed, but no date Terminated 2019-002063-95 A Phase 3, Open, Randomized controlled trial on Completion Rate of daily Rifapentine/Isoniazid for One Month Compared with Daily Rifampicin/Isoniazid for Three Months for the Treatment of Latent Tuber... bad-data
Ongoing 2020-000295-38 Phase II trial, open label, single-arm, of Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions Studio di fase II, in aperto, a braccio singolo su inibitore del checkpoint immunitario... not-yet-due
Ongoing 2020-004530-38 PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENALCORTICAL (PESETA TRIAL)... not-yet-due
Ongoing 2020-005754-23 Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial) RADIOTERAPIA STEREOTASSICA PROSTATICA CON O SENZA T... not-yet-due
Ongoing 2021-000520-35 Multiparametric assessment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study VALUTAZIONE MULTIPARAM... not-yet-due
Ongoing 2021-001438-20 Randomized controlled trial on daily Rifampicin for Four Months Compared with daily Rifampicin/Isoniazid for Three Months for the Treatment of Tuberculosis Infection among migrants: Completion Rate an... not-yet-due
Ongoing 2021-006515-28 Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) p... not-yet-due
Ongoing 2022-002841-17 Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell c... not-yet-due
Ongoing 2022-003206-69 A multicenter, randomized, open-label, controlled study to evaluate the efficacy and safety of corticoSTEROids added to standard therapy in patients with Acute Heart Failure (STERO-AHF) Studio mult... not-yet-due
Ongoing 2022-004188-25 P-ACC Trial - Phase II, single arm, multicenter, open-label study of PARP inhibitors + cisplatin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma P-ACC Trial: Studio di fase II; singolo brac... not-yet-due